Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 7/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 7/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491875 | 0.83 | CNR2 (0.39) | PLK1 | |
| SCHEMBL15751962 | 0.79 | SCN5A (0.39) | GUCY1A1GUCY1B1KMOPDE5AKDM4C | |
| SCHEMBL1552045 | 0.69 | GRM2 (0.45) | GUCY1A1GUCY1B1PDE5AMAPK8CYP2C9 | |
| SCHEMBL21413147 | 0.68 | KDM4C (0.41) | GUCY1A1GUCY1B1KMOPDE5AKDM4C | |
| SCHEMBL15792111 | 0.67 | KDM4C (0.50) | GUCY1A1GUCY1B1KMOPDE5AKDM4C | |
| SCHEMBL6114329 | 0.66 | SLC9A1 (0.45) | — | |
| SCHEMBL17610151 | 0.66 | KDM4C (0.45) | KMOPDE5AKDM4CPLK1MAT2A | |
| SCHEMBL13885733 | 0.65 | CNR2 (0.51) | — | |
| SCHEMBL14776630 | 0.65 | PDE5A (0.49) | GUCY1A1GUCY1B1KMOPDE5A | |
| SCHEMBL19597176 | 0.64 | KDM4C (0.50) | KMOKDM4CPLK1DYRK3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417111-B1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI SA (FR) | 2014-06-04 | — | — | EP | disclosed |
| US-8420651-B2 | Substituted 1-alkylcinnolin-4(1H)-one derivatives, preparation thereof and therapeutic application of same | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| EP-2417111-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116084-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | ALK, CBR1, CBR3 | GUCY1A1 3893/4885GUCY1B1 3147/4885KMO 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.